Reduced health care use for exenatide regimens in T2DM

March 2, 2017

(HealthDay)—For patients with type 2 diabetes, treatment with exenatide is associated with reduced health care resource use and costs compared with basal insulin (BI) regimens, according to a study published online Feb. 20 in Diabetes, Obesity and Metabolism.

In a , Sarah E. Holden, from Pharmatelligence in Cardiff, U.K., and colleagues estimated heath care resource use and related financial costs following exenatide-based regimens prescribed as once-weekly (EQW) or twice-daily (EBID) formulations versus BI regimens. Data were included for with type 2 prescribed exenatide or BI between 2009 and 2014 as their first recorded exposure to injectable therapy. A total of 8,723, 218, and 2,180 patients prescribed BI, EQW, and EBID, respectively, were included in the study. Overall, 188 patients prescribed EQW and 1,486 prescribed EBID were propensity score-matched to BI patients in a 1:1 ratio.

The researchers found that total crude mean costs per patient-year were £2,765, £2,549, and £4,080 for EQW, EBID, and BI, respectively, among unmatched cohorts. The adjusted annual cost ratio was 0.92 and 0.82 for EQW and EBID, respectively, compared with BI. For the propensity score-matched subgroups, the corresponding costs were £2,646 versus £3,283 for EQW versus BI and £2,532 versus £3,070 for EBID versus BI.

"Overall, treatment with EQW and EBID was associated with reduced health care resource use and compared with BI," the authors write.

Several authors disclosed financial ties to Pharmatelligence. One author is an employee of AstraZeneca, which commercializes exenatide and funded the study.

Explore further: Exenatide twice daily deemed efficacious across BMI ranges

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Exenatide twice daily deemed efficacious across BMI ranges

April 11, 2016
(HealthDay)—For patients with type 2 diabetes, exenatide twice daily added to insulin glargine is efficacious across body mass index (BMI) ranges, according to a study published online March 29 in Diabetes, Obesity and ...

Exenatide does not promote weight loss in schizophrenia

October 5, 2016
(HealthDay)—For antipsychotic-treated obese patients with schizophrenia, glucagon-like peptide-1 receptor agonists (GLP-1RAs) do not appear to promote weight loss, according to a study published online Sept. 26 in Diabetes, ...

Exenatide, pioglitazone effective for poorly controlled T2DM

January 23, 2017
(HealthDay)—For patients with long-standing poorly controlled type 2 diabetes mellitus (T2DM) on metformin plus a sulfonylurea, combination therapy with exenatide and pioglitazone is effective and safe, according to a study ...

Diabetes requiring insulin tied to increased stroke risk in A-fib

January 26, 2017
(HealthDay)—For patients with atrial fibrillation (AF), diabetes requiring insulin, but not diabetes without insulin treatment, is associated with an increased risk of stroke/systemic embolism, according to a study published ...

Novel oral glucose lowering drugs cut risks in T2DM

February 8, 2017
(HealthDay)—For patients with type 2 diabetes, novel oral glucose lowering drugs (GLDs) are associated with reduced risks of all-cause mortality, cardiovascular disease (CVD), and hypoglycemia, compared with insulin use, ...

Economic burden of binge-eating disorder quantified

November 21, 2016
(HealthDay)—Individuals with binge-eating disorder (BED) have significantly greater economic burden compared to those without BED, according to a study published online Nov. 16 in the International Journal of Eating Disorders.

Recommended for you

Can't exercise? A hot bath may help improve inflammation, metabolism, study suggests

November 14, 2018
Hot water treatment may help improve inflammation and blood sugar (glucose) levels in people who are unable to exercise, according to a new study. The findings are published ahead of print in the Journal of Applied Physiology.

Diabetic foot ulcers heal quickly with nitric oxide technology

November 12, 2018
Diabetic foot ulcers can take up to 150 days to heal. A biomedical engineering team wants to reduce it to 21 days.

Diabetes drug might also ease heart failure risks

November 12, 2018
(HealthDay)—The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows.

Marijuana use tied to serious diabetes complication

November 8, 2018
(HealthDay)—People with type 1 diabetes who use marijuana may double their risk of developing a life-threatening complication, a new study suggests.

Researchers report connection between intestinal bacteria and development of diabetes

November 7, 2018
Researchers at Örebro University have, together with a well-known research team in Denmark, developed a method for studying how metabolism in gut bacteria influences health. Their method will now be published in its entirety ...

Genetic factors tied to obesity may protect against diabetes

November 2, 2018
Some genetic variations linked with obesity actually protect against Type 2 diabetes, heart attack and stroke, new findings suggest.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.